Skip to main content

AtriCure, Inc.

corporate_fare Company Profile

AtriCure, Inc.

ATRC·NASDAQ·Industrial Applications And Services·CIK 0001323885

We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. Afib is an irregular heartbeat affecting over 59 million people worldwide. Our cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. In open-heart procedures, our products are used alongside other heart surgeries like mitral or aortic valve repair or coronary artery bypass. Minimally invasive procedures are performed independently and often combine surgical procedures using our ablation and LAAM products with catheter ablation. Our pain management solutions are used by physicians to freeze nerves during cardiac, thoracic, or amputation surgical procedures. These solutions include our cryoICE cryoSPHERE ® and cryoXT™ probes for pain management, known as Cryo Nerve Block. These products provide temporary relief of post-operative pain, allowing healing while nerves regenerate.

AtriCure, Inc. (NASDAQ:ATRC) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for ATRC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for ATRC spans 10-Q, 8-K, 8-K/A, DEF 14A.

Recent high-impact activity:

  • AtriCure 10-Q: Q3 Revenue $154.5M, First Nine-Month Profit, $260M SentreHEART Suit Detailed
  • AtriCure Beats Growth Bar With 15% Revenue Rise, Raises Full-Year Outlook to $610M
  • AtriCure Q3 Revenue Up 15% to $154.5M; Full-Year Guidance Set at $606-610M
  • AtriCure Swings to Q2 Profit on 12.8% Revenue Growth; SentreHEART Lawsuit Seeks $260M
  • AtriCure Swings to Profit in Q2, Raises Full-Year Profitability Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$534.53M
Net Income
-$11.45M
Diluted EPS
-$0.24
Op. Cash Flow
$57.33M
Free Cash Flow
$48.28M
Gross Profit
$400.78M
Operating Income
-$9.45M
Cash & Equivalents
$167.43M
Total Debt
$61.87M
Debt / Equity
0.13×
Net Margin
-2.1%
Shares Outstanding
49.79M sh
Source: 10-K · filed 2026-02-19 · accession 0001323885-26-000007

Short Interest & Short Volume

7.60 days to cover

FINRA reported short interest of 4,889,793 shares in ATRC as of the October 30, 2026 settlement, a 0.1% increase from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 68.2% of ATRC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)4,889,793 shares as of October 30, 2026
Change vs prior period▲ 0.1%
Days to cover7.60 at avg daily volume of 643,486
Daily short volume (FINRA facilities)68.2% of 177,082 shares on November 20, 2026
5-day average short volume60.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$55.39
52-week range · as of 2026-11-04 $25.36 – $65
Market cap
$2.82B
Volume
813.1K (1.1× avg)
3-mo avg 750.3K
Live data · 2026-11-21 19:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATRC - Latest Insights

ATRC
Nov 04, 2026, 2:02 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $64.90
Real-time Price: $55.39 info
Change: -$9.50 (-15%) info
Market Cap: $2.821B info
ATRC
Nov 03, 2026, 4:01 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $60.41
Real-time Price: $55.39 info
Change: -$5.02 (-8%) info
Market Cap: $2.821B info
ATRC
Nov 03, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $60.35
Real-time Price: $55.39 info
Change: -$4.96 (-8%) info
Market Cap: $2.821B info
ATRC
Jul 27, 2026, 1:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $37.31
Real-time Price: $55.39 info
Change: +$18.08 (+48%) info
Market Cap: $2.821B info
ATRC
Jul 23, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $34.71
Real-time Price: $55.39 info
Change: +$20.68 (+60%) info
Market Cap: $2.821B info
ATRC
May 19, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $28.80
Real-time Price: $55.39 info
Change: +$26.59 (+92%) info
Market Cap: $2.821B info
ATRC
May 05, 2026, 9:01 PM EDT
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $30.40
Real-time Price: $55.39 info
Change: +$24.99 (+82%) info
Market Cap: $2.821B info
ATRC
May 05, 2026, 4:23 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $29.50
Real-time Price: $55.39 info
Change: +$25.89 (+88%) info
Market Cap: $2.821B info
ATRC
May 05, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.39
Real-time Price: $55.39 info
Change: +$26.00 (+88%) info
Market Cap: $2.821B info
ATRC
Apr 06, 2026, 11:54 AM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $29.33
Real-time Price: $55.39 info
Change: +$26.06 (+89%) info
Market Cap: $2.821B info
ATRC
Feb 19, 2026, 12:39 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $32.39
Real-time Price: $55.39 info
Change: +$23.01 (+71%) info
Market Cap: $2.821B info
ATRC
Feb 17, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $32.97
Real-time Price: $55.39 info
Change: +$22.42 (+68%) info
Market Cap: $2.821B info
ATRC
Jan 12, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $41.46
Real-time Price: $55.39 info
Change: +$13.93 (+34%) info
Market Cap: $2.821B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets